Telomere length and genetic variant associations with interstitial lung disease progression and survival

European Respiratory Journal

Volumn 53, Issue 4, 2019, Pages

  Newton, Chad A ^a   Oldham, Justin M ^b   Ley, Brett ^c   Anand, Vikram ^a   Adegunsoye, Ayodeji ^d   Liu, Gabrielle ^c   Batra, Kiran ^a   Torrealba, Jose ^a   Kozlitina, Julia ^e   Glazer, Craig ^a   Strek, Mary E ^d   Wolters, Paul J ^c   Noth, Imre ^f   Garcia, Christine Kim ^a,e  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUCIN 5B; MUC5B PROTEIN, HUMAN; SIGNAL PEPTIDE; TOLLIP PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LONGITUDINAL STUDY; LUNG ARTERY PRESSURE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MARKER GENE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; TELOMERE LENGTH; TRANSPLANT FREE SURVIVAL; GENETIC VARIATION; GENETICS; LEUKOCYTE; MIDDLE AGED; MORTALITY; TELOMERE; ULTRASTRUCTURE;

AGED; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GENETIC VARIATION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKOCYTES; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MUCIN-5B; RETROSPECTIVE STUDIES; SURVIVAL RATE; TELOMERE;

EID: 85062701792     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01641-2018     Document Type: Article

References (40)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
2. Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366: 1968-1977.
3. Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 2016; 4: 708-719.
4. Vij R, Strek ME. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest 2013; 143: 814-824.
5. Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 2013; 40: 640-646.
6. Fischer A, Antoniou KM, Brown KK, et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 2015; 46: 976-987.
7. Oldham JM, Adegunsoye A, Valenzi E, et al. Characterisation of patients with interstitial pneumonia with autoimmune features. Eur Respir J 2016; 47: 1767-1775.
8. Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 2011; 364: 1503-1512.
9. Fingerlin TE, Murphy E, Zhang W, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet 2013; 45: 613-620.
10. Noth I, Zhang Y, Ma SF, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med 2013; 1: 309-317.
11. Peljto AL, Zhang Y, Fingerlin TE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA 2013; 309: 2232-2239.
12. Dressen A, Abbas AR, Cabanski C, et al. Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study. Lancet Respir Med 2018; 6: 603-614.
13. Newton CA, Batra K, Torrealba J, et al. Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive. Eur Respir J 2016; 48: 1710-1720.
14. Stuart BD, Lee JS, Kozlitina J, et al. Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation. Lancet Respir Med 2014; 2: 557-565.
15. Dai J, Cai H, Li H, et al. Association between telomere length and survival in patients with idiopathic pulmonary fibrosis. Respirology 2015; 20: 947-952.
16. Snetselaar R, van Batenburg AA, van Oosterhout MFM, et al. Short telomere length in IPF lung associates with fibrotic lesions and predicts survival. PLoS One 2017; 12: e0189467.
17. Ley B, Newton CA, Arnould I, et al. The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: an observational cohort-control study. Lancet Respir Med 2017; 5: 639-647.
18. Cronkhite JT, Xing C, Raghu G, et al. Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 178: 729-737.
19. Diaz de Leon A, Cronkhite JT, Katzenstein AL, et al. Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations. PLoS One 2010; 5: e10680.
20. 1000 Genomes Project Consortium, Auton A, Brooks LD, et al. A global reference for human genetic variation. Nature 2015; 526: 68-74.
21. Ahmad K, Barba T, Gamondes D, et al. Interstitial pneumonia with autoimmune features: clinical, radiologic, and histological characteristics and outcome in a series of 57 patients. Respir Med 2017; 123: 56-62.
22. Snetselaar R, van Moorsel CH, Kazemier KM, et al. Telomere length in interstitial lung diseases. Chest 2015; 148: 1011-1018.
23. Borie R, Crestani B, Dieude P, et al. The MUC5B variant is associated with idiopathic pulmonary fibrosis but not with systemic sclerosis interstitial lung disease in the European caucasian population. PLoS One 2013; 8: e70621.
24. Stock CJ, Sato H, Fonseca C, et al. Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax 2013; 68: 436-441.
25. Peljto AL, Steele MP, Fingerlin TE, et al. The pulmonary fibrosis-associated MUC5B promoter polymorphism does not influence the development of interstitial pneumonia in systemic sclerosis. Chest 2012; 142: 1584-1588.
26. van der Vis JJ, Snetselaar R, Kazemier KM, et al. Effect of MUC5B promoter polymorphism on disease predisposition and survival in idiopathic interstitial pneumonias. Respirology 2016; 21: 712-717.
27. Kelly CA, Saravanan V, Nisar M, et al. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics-a large multicentre UK study. Rheumatology (Oxford) 2014; 53: 1676-1682.
28. Doyle TJ, Dellaripa PF, Batra K, et al. Functional impact of a spectrum of interstitial lung abnormalities in rheumatoid arthritis. Chest 2014; 146: 41-50.
29. Weyand CM, Schmidt D, Wagner U, et al. The influence of sex on the phenotype of rheumatoid arthritis. Arthritis Rheum 1998; 41: 817-822.
30. Saag KG, Cerhan JR, Kolluri S, et al. Cigarette smoking and rheumatoid arthritis severity. Ann Rheum Dis 1997; 56: 463-469.
31. Kim EJ, Collard HR, King TE Jr. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest 2009; 136: 1397-1405.
32. Assayag D, Elicker BM, Urbania TH, et al. Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern. Radiology 2014; 270: 583-588.
33. Juge PA, Lee JS, Ebstein E, et al. MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease. N Engl J Med 2018; 379: 2209-2219.
34. Juge PA, Borie R, Kannengiesser C, et al. Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis. Eur Respir J 2017; 49: 1602314.
35. Petrovski S, Todd JL, Durheim MT, et al. An exome sequencing study to assess the role of rare genetic variation in pulmonary fibrosis. Am J Respir Crit Care Med 2017; 196: 82-93.
36. Tsakiri KD, Cronkhite JT, Kuan PJ, et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci USA 2007; 104: 7552-7557.
37. Armanios MY, Chen JJ, Cogan JD, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007; 356: 1317-1326.
38. Stuart BD, Choi J, Zaidi S, et al. Exome sequencing links mutations in PARN and RTEL1 with familial pulmonary fibrosis and telomere shortening. Nat Genet 2015; 47: 512-517.
39. Kannengiesser C, Borie R, Menard C, et al. Heterozygous RTEL1 mutations are associated with familial pulmonary fibrosis. Eur Respir J 2015; 46: 474-485.
40. Gutierrez-Rodrigues F, Santana-Lemos BA, Scheucher PS, et al. Direct comparison of flow-FISH and qPCR as diagnostic tests for telomere length measurement in humans. PLoS One 2014; 9: e113747.